Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E-mutated colorectal cancer.

European journal of cancer (Oxford, England : 1990) - 1 Apr 2021

Stammler Romain, Gallois Claire, Taieb Julien, Duong Jean-Paul, Karras Alexandre, Thervet Eric, Lazareth Hélène

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Kidney Injury
Share to Antineoplastic Combined Chemotherapy Protocols
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbamates

Share to Cetuximab

Share to Glomerular Filtration Rate

Share to Recovery of Function

Share to Sulfonamides

Source

Identifiers

PMID: 33618199
DOI: 10.1016/j.ejca.2021.01.024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E-mutated colorectal cancer.PMID 33618199Read ↗

Gastric and rectal administration of encorafenib with targeted chemotherapy against BRAF V600E-mutant rectal cancer with bowel obstruction.Semantic proximity Read ↗

Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study.Semantic proximity Read ↗

[A Case of BRAF Mutant Cecal Cancer Treated with Encorafenib, Binimetinib, and Cetuximab Triple Therapy].Semantic proximity Read ↗

The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy.Semantic proximity Read ↗

Relatively mild symptoms after chronic overdose with a double-dose encorafenib: a case report.Semantic proximity Read ↗

Successful Management of BRAF V600E-Mutated Metastatic Colorectal Cancer With Liver Dysfunction Using Encorafenib-Based Therapy.Semantic proximity Read ↗

BRAF V600E-mutant colorectal cancer with CNS metastases treated successfully with encorafenib, binimetinib and cetuximab.Semantic proximity Read ↗

Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.Semantic proximity Read ↗

Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib.Semantic proximity Read ↗

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal CancerSemantic proximity Read ↗

Third-Line Treatment Options for Kidney Cancer.Semantic proximity Read ↗

Adverse Renal Effects of Anticancer Immunotherapy: A ReviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.